These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 22652154)
1. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Hetland TE; Nymoen DA; Emilsen E; Kærn J; Tropé CG; Flørenes VA; Davidson B Gynecol Oncol; 2012 Sep; 126(3):460-5. PubMed ID: 22652154 [TBL] [Abstract][Full Text] [Related]
2. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921 [TBL] [Abstract][Full Text] [Related]
3. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077 [TBL] [Abstract][Full Text] [Related]
5. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113 [TBL] [Abstract][Full Text] [Related]
6. Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Weiss I; Trope CG; Reich R; Davidson B Int J Mol Sci; 2012 Oct; 13(10):12925-38. PubMed ID: 23202930 [TBL] [Abstract][Full Text] [Related]
7. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403 [TBL] [Abstract][Full Text] [Related]
8. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. Davidson B; Holth A; Nguyen MT; Tropé CG; Wu C Gynecol Oncol; 2013 Feb; 128(2):364-70. PubMed ID: 23099104 [TBL] [Abstract][Full Text] [Related]
9. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111 [TBL] [Abstract][Full Text] [Related]
10. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Vaksman O; Davidson B; Tropé C; Reich R Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004 [TBL] [Abstract][Full Text] [Related]
12. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216 [TBL] [Abstract][Full Text] [Related]
13. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408 [TBL] [Abstract][Full Text] [Related]
14. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Davidson B; Baekelandt M; Shih IeM Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338 [TBL] [Abstract][Full Text] [Related]
15. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. Broner EC; Tropé CG; Reich R; Davidson B Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812 [TBL] [Abstract][Full Text] [Related]
16. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938 [TBL] [Abstract][Full Text] [Related]
17. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507 [TBL] [Abstract][Full Text] [Related]
18. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361 [TBL] [Abstract][Full Text] [Related]
19. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Bock AJ; Tuft Stavnes H; Kærn J; Berner A; Staff AC; Davidson B Tumour Biol; 2011 Jun; 32(3):589-96. PubMed ID: 21350924 [TBL] [Abstract][Full Text] [Related]
20. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]